Innovators in Complex Carbohydrate Chemistry

We are a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes.

View Pipeline

Boston Therapeutics, Inc. (BTHE)

About Boston Therapeutics, Inc.

A non-toxic, chewable diabetic solution

BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications.

Learn more about BTI-320

About Boston Therapeutics, Inc.

The cell bodyguard

IPOXYN™, is an injectable Rx for prevention of necrosis and treatment of ischemic conditions which may lead to necrosis.

Learn more about IPOXYN

About Boston Therapeutics, Inc.

About Boston Therapeutics

We are a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes.

Learn more

Boston Therapeutics, Inc. Investor Information

Investors

OTCQB: BTHE
Market Cap:

View Investor Relations